Skip to content

Supartz

by Seikagaku Corp.

PMA P980044

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

PMA P980044↗

FDA record

Trust

Unverified

Source FDA PMA, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved NumberP980044 Date24 Jan 2001ApprovedStatusActive

Official records

From the FDA record

FDA PMA P980044

Received by the FDA
1 Dec 1998
FDA decision
24 Jan 2001
FDA review time
785 days from receipt to decision
Docket number
01M-0342
Approval order statement, verbatim
APPROVAL FOR THE SUPARTZ(TM) DISPO. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.

From the FDA PMA record P980044 (openFDA), as read on 22 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Trade name
Supartz Fx
Generic name
Acid, hyaluronic, intraarticular
PMA number
FDA product code
MOZ
Device class
Class III
Advisory committee
Orthopedic
FDA decision
APPR Approved

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

Supartz is a hyaluronic acid intraarticular injection indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, such as acetaminophen. It is supplied as a sterile, single-use product for intraarticular administration.

The device is manufactured by Seikagaku Corp. and received FDA PMA approval (P980044) on January 24, 2001. It is intended for use in device class 3 and is indicated specifically for intraarticular use in the knee joint for osteoarthritis pain management.

Devices cleared under P980044

6 devices · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under P980044
UDI-DISize and differences
Supartz
ALLY MEDICAL SUPPLIES LTD
NA05060459970120 —On the market
Supartz
PAVAN TRADING LTD
None05060548950057 —On the market
SUPARTZ FX sodium hyaluronate 71564444
BIOVENTUS LLC
7156444410389130444418 —On the market
SUPARTZ FX sodium hyaluronate 89130-4444-1
SEIKAGAKU CORPORATION
7156-4444 / 89130-4444-1M717715644440 —No longer on the market
SUPARTZ® sodium hyaluronate 89130-5555-01
SEIKAGAKU CORPORATION
7156-5555 / 89130-5555-01M717715655550 —No longer on the market
VISCO-3 sodium hyaluronate 00-1111-001-03
SEIKAGAKU CORPORATION
00-1111-001-03 / 00-1111-001-0304987541301314 —On the market

Similar devices

Other devices filed under FDA product code MOZ (Acid, Hyaluronic, Intraarticular).

Other devices from Seikagaku Corp.